Weight loss: Hims & Hers introduce access to GLP-1 injections

Hims & Hers Health (HIMS) stock has jumped up upon the telehealth provider introducing compounding injectable GLP-1 weight-loss drugs to its services. Yahoo Finance's Jared Blikre and Julie Hyman report on Hims & Hers' latest offering in the weight-loss drug category.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Luke Carberry Mogan and updated by Melanie Riehl

Video transcript

Shares of Digital Pharmacy hymns and hers surging this morning after announcing access to G LP one weight loss drugs, the company planning to price a compounded injection starting just around 100 and 99 bucks a month.

So when you take a look at the reaction that we're seeing play out in the market right now, you're looking at shares up nearly 11% here at the open when it comes to what we are learning within this news here.

Clearly, this could be a huge win for the company going forward when it comes to exactly what this means here for him.

And there is a firm saying that the treatment offers the same active ingredient as G LP ones and we govi copycat drug made by undisclosed compounding pharmacy.

So it's an important uh difference here that we do want to know.

But again, the street is excited about this and you're looking at gains of nearly 11% Brad.

I mean, we're getting to the point where we're starting to see advertisements for some of the solutions and I mean, move over wearables and embeds.

I guess this is an embedded technology.

If you will injectables, but ultimately for him, hers and, uh, all of the other businesses that are trying to make sure that they don't miss out on the G LP ones.

II, I guess, where do you reinvest some of those profits is gonna be the next question for investors to make sure that you're ahead of the next R and D development or R and D phase, research and development phases for, I, I don't know what people decided to decide to do after this, but, uh, once you've lost all that weight, you gotta figure out something.

Yeah.

Yeah, you do.

And, and, and then that, that's the other part of this conversation too, just in terms of what that demand is going to look like.

Going forward exactly what the ne is.

What happens when people do get off the drugs, if they do decide to get off these drugs.

But him and hers at least seeing a reason to try and get into this phase surrounding the hypes and the company saying in the press release that the, that this drug, uh, that this is gonna help customers access these drugs without quote navigating the shortages and costs that are currently limiting access to the branded medications here.

So again, shares jumping just about 15% in early trading.